284 related articles for article (PubMed ID: 27384421)
21. THZ1 reveals CDK7-dependent transcriptional addictions in pancreatic cancer.
Lu P; Geng J; Zhang L; Wang Y; Niu N; Fang Y; Liu F; Shi J; Zhang ZG; Sun YW; Wang LW; Tang Y; Xue J
Oncogene; 2019 May; 38(20):3932-3945. PubMed ID: 30692639
[TBL] [Abstract][Full Text] [Related]
22. Triptolide suppresses proliferation, hypoxia-inducible factor-1α and c-Myc expression in pancreatic cancer cells.
Ding X; Zhou X; Jiang B; Zhao Q; Zhou G
Mol Med Rep; 2015 Sep; 12(3):4508-4513. PubMed ID: 26094625
[TBL] [Abstract][Full Text] [Related]
23. A PET Imaging Strategy for Interrogating Target Engagement and Oncogene Status in Pancreatic Cancer.
Henry KE; Dacek MM; Dilling TR; Caen JD; Fox IL; Evans MJ; Lewis JS
Clin Cancer Res; 2019 Jan; 25(1):166-176. PubMed ID: 30228208
[TBL] [Abstract][Full Text] [Related]
24. LINC00346 promotes pancreatic cancer progression through the CTCF-mediated Myc transcription.
Peng WX; He RZ; Zhang Z; Yang L; Mo YY
Oncogene; 2019 Oct; 38(41):6770-6780. PubMed ID: 31391552
[TBL] [Abstract][Full Text] [Related]
25. FASTKD2 promotes cancer cell progression through upregulating Myc expression in pancreatic ductal adenocarcinoma.
Fang R; Zhang B; Lu X; Jin X; Liu T
J Cell Biochem; 2020 Mar; 121(3):2458-2466. PubMed ID: 31692063
[TBL] [Abstract][Full Text] [Related]
26. Application of a MYC degradation screen identifies sensitivity to CDK9 inhibitors in KRAS-mutant pancreatic cancer.
Blake DR; Vaseva AV; Hodge RG; Kline MP; Gilbert TSK; Tyagi V; Huang D; Whiten GC; Larson JE; Wang X; Pearce KH; Herring LE; Graves LM; Frye SV; Emanuele MJ; Cox AD; Der CJ
Sci Signal; 2019 Jul; 12(590):. PubMed ID: 31311847
[TBL] [Abstract][Full Text] [Related]
27. A gene expression signature of epithelial tubulogenesis and a role for ASPM in pancreatic tumor progression.
Wang WY; Hsu CC; Wang TY; Li CR; Hou YC; Chu JM; Lee CT; Liu MS; Su JJ; Jian KY; Huang SS; Jiang SS; Shan YS; Lin PW; Shen YY; Lee MT; Chan TS; Chang CC; Chen CH; Chang IS; Lee YL; Chen LT; Tsai KK
Gastroenterology; 2013 Nov; 145(5):1110-20. PubMed ID: 23896173
[TBL] [Abstract][Full Text] [Related]
28. Triptolide is an inhibitor of RNA polymerase I and II-dependent transcription leading predominantly to down-regulation of short-lived mRNA.
Vispé S; DeVries L; Créancier L; Besse J; Bréand S; Hobson DJ; Svejstrup JQ; Annereau JP; Cussac D; Dumontet C; Guilbaud N; Barret JM; Bailly C
Mol Cancer Ther; 2009 Oct; 8(10):2780-90. PubMed ID: 19808979
[TBL] [Abstract][Full Text] [Related]
29. The Sustained Induction of c-MYC Drives Nab-Paclitaxel Resistance in Primary Pancreatic Ductal Carcinoma Cells.
Parasido E; Avetian GS; Naeem A; Graham G; Pishvaian M; Glasgow E; Mudambi S; Lee Y; Ihemelandu C; Choudhry M; Peran I; Banerjee PP; Avantaggiati ML; Bryant K; Baldelli E; Pierobon M; Liotta L; Petricoin E; Fricke ST; Sebastian A; Cozzitorto J; Loots GG; Kumar D; Byers S; Londin E; DiFeo A; Narla G; Winter J; Brody JR; Rodriguez O; Albanese C
Mol Cancer Res; 2019 Sep; 17(9):1815-1827. PubMed ID: 31164413
[TBL] [Abstract][Full Text] [Related]
30. Glucose Metabolism Reprogrammed by Overexpression of IKKε Promotes Pancreatic Tumor Growth.
Zubair H; Azim S; Srivastava SK; Ahmad A; Bhardwaj A; Khan MA; Patel GK; Arora S; Carter JE; Singh S; Singh AP
Cancer Res; 2016 Dec; 76(24):7254-7264. PubMed ID: 27923829
[TBL] [Abstract][Full Text] [Related]
31. Epigenetic drug screening defines a PRMT5 inhibitor-sensitive pancreatic cancer subtype.
Orben F; Lankes K; Schneeweis C; Hassan Z; Jakubowsky H; Krauß L; Boniolo F; Schneider C; Schäfer A; Murr J; Schlag C; Kong B; Öllinger R; Wang C; Beyer G; Mahajan UM; Xue Y; Mayerle J; Schmid RM; Kuster B; Rad R; Braun CJ; Wirth M; Reichert M; Saur D; Schneider G
JCI Insight; 2022 May; 7(10):. PubMed ID: 35439169
[TBL] [Abstract][Full Text] [Related]
32. Rho Kinase Inhibition by AT13148 Blocks Pancreatic Ductal Adenocarcinoma Invasion and Tumor Growth.
Rath N; Munro J; Cutiongco MF; Jagiełło A; Gadegaard N; McGarry L; Unbekandt M; Michalopoulou E; Kamphorst JJ; Sumpton D; Mackay G; Vennin C; Pajic M; Timpson P; Olson MF
Cancer Res; 2018 Jun; 78(12):3321-3336. PubMed ID: 29669760
[TBL] [Abstract][Full Text] [Related]
33. DFMO Improves Survival and Increases Immune Cell Infiltration in Association with MYC Downregulation in the Pancreatic Tumor Microenvironment.
Nakkina SP; Gitto SB; Beardsley JM; Pandey V; Rohr MW; Parikh JG; Phanstiel O; Altomare DA
Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34947972
[TBL] [Abstract][Full Text] [Related]
34. Triptolide-induced cell death in pancreatic cancer is mediated by O-GlcNAc modification of transcription factor Sp1.
Banerjee S; Sangwan V; McGinn O; Chugh R; Dudeja V; Vickers SM; Saluja AK
J Biol Chem; 2013 Nov; 288(47):33927-33938. PubMed ID: 24129563
[TBL] [Abstract][Full Text] [Related]
35. Activation of vitamin D receptor signaling downregulates the expression of nuclear FOXM1 protein and suppresses pancreatic cancer cell stemness.
Li Z; Jia Z; Gao Y; Xie D; Wei D; Cui J; Mishra L; Huang S; Zhang Y; Xie K
Clin Cancer Res; 2015 Feb; 21(4):844-53. PubMed ID: 25501129
[TBL] [Abstract][Full Text] [Related]
36. Overexpression of SOX18 correlates with accelerated cell growth and poor prognosis in human pancreatic ductal adenocarcinoma.
Wang Y; Guo H; Zhang D; Yu X; Leng X; Li S; Zhu W
Biochem Biophys Res Commun; 2016 Oct; 479(3):510-516. PubMed ID: 27663663
[TBL] [Abstract][Full Text] [Related]
37. FL118, acting as a 'molecular glue degrader', binds to dephosphorylates and degrades the oncoprotein DDX5 (p68) to control c-Myc, survivin and mutant Kras against colorectal and pancreatic cancer with high efficacy.
Ling X; Wu W; Aljahdali IAM; Liao J; Santha S; Fountzilas C; Boland PM; Li F
Clin Transl Med; 2022 May; 12(5):e881. PubMed ID: 35604033
[TBL] [Abstract][Full Text] [Related]
38. MYC regulates ductal-neuroendocrine lineage plasticity in pancreatic ductal adenocarcinoma associated with poor outcome and chemoresistance.
Farrell AS; Joly MM; Allen-Petersen BL; Worth PJ; Lanciault C; Sauer D; Link J; Pelz C; Heiser LM; Morton JP; Muthalagu N; Hoffman MT; Manning SL; Pratt ED; Kendsersky ND; Egbukichi N; Amery TS; Thoma MC; Jenny ZP; Rhim AD; Murphy DJ; Sansom OJ; Crawford HC; Sheppard BC; Sears RC
Nat Commun; 2017 Nov; 8(1):1728. PubMed ID: 29170413
[TBL] [Abstract][Full Text] [Related]
39. Targeting the ubiquitin-proteasome system in a pancreatic cancer subtype with hyperactive MYC.
Lankes K; Hassan Z; Doffo MJ; Schneeweis C; Lier S; Öllinger R; Rad R; Krämer OH; Keller U; Saur D; Reichert M; Schneider G; Wirth M
Mol Oncol; 2020 Dec; 14(12):3048-3064. PubMed ID: 33099868
[TBL] [Abstract][Full Text] [Related]
40. Therapeutic effects of an anti-Myc drug on mouse pancreatic cancer.
Stellas D; Szabolcs M; Koul S; Li Z; Polyzos A; Anagnostopoulos C; Cournia Z; Tamvakopoulos C; Klinakis A; Efstratiadis A
J Natl Cancer Inst; 2014 Dec; 106(12):. PubMed ID: 25306215
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
